Predictive, Preventive & Personalized Medicine and Molecular Diagnostics

Biography

Biography: Havva Keskin

Abstract

The daily taking of a low-dose aspirin has become more common when dealing with cardiovascular and cerebrovascular issues in the past century. Evidence from the re-examination of the case control and cohort studies which were designed primarly to assess different diseases showed that the taking of a daily low dose aspirin in the long term not only decreases the frequencies of these mentioned diseases but also leads to a decrease in the frequency of certain cancers especially colorectal cancer. However, some of the cilinical trials show a positive effect while some decelerated ineffectivenees and even showed a negative effect on some kind of cancers. An important point is that specific populations take the daily low dose aspirin in the long term, compared to the general healthy population. This point may be a significant bias in these large trials. To break down this bias, more interventional cohorts should be set up at diffrent socioeconomic populations in different countries. Most of the participants take different drugs due to different comorbidities. These comorbid diseases can also cause inflammation and the development of various cancers. It has been displayed there is some possible effect of usage of aspirin in cancer chemoprevention, but the mechanisms are not still clear. As a result, taking daily low dose aspirin in cancer primary prevention remains controversial. The latest meta analyses have been very encouraging especially the taking daily low dose long term aspirin to prevent cancer, but the current consensus is: not yet. There is a need for more randomized controlled trials, interventional trials, systematic reviews and meta-analyses.